Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BASF and Dyadic Enter Into Research Agreement

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
Dyadic’s C1 technology platform enables BASF to develop enzymes for multiple market segments.

BASF and Dyadic International, Inc. have announced that the two Companies have entered into a non-exclusive worldwide research and license agreement.

Under the terms of the agreement, BASF will be able to use Dyadic’s patented and proprietary C1 platform technology to develop, produce, distribute and sell industrial enzymes in certain fields for a variety of applications.

BASF will fund research and development at Dyadic’s research lab in The Netherlands. In addition to this funding, BASF has agreed to pay Dyadic a $6 million upfront license fee, and certain research and commercial milestone fees, as well as royalties upon commercialization.

“Dyadic’s C1 technology will strengthen BASF’s position in the industrial enzyme industry,” said Dr. Carsten Sieden, Senior Vice President Fine Chemicals and Biocatalysis Research, BASF. “We expect this license agreement with Dyadic to result in promising long-term opportunities.”

Dyadic’s President and Chief Executive Officer, Mark Emalfarb, stated, “Empowering BASF, the world’s leading chemical company, with our C1 technology provides them with access to a commercially-proven industrial enzyme production platform. In using its vast resources to develop, manufacture and sell new products from the C1 platform, BASF will have business opportunities for a variety of markets, including animal and human nutrition. This transaction will have long-lasting effects on the industrial enzyme businesses of both Dyadic and BASF.”

Emalfarb concluded, “Dyadic looks forward to working with BASF and utilizing our C1 technology for the expression of next-generation enzyme products for a range of applications. This collaboration is yet another example of Dyadic’s ability to leverage our technologies in a variety of industries.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NEW U.S. Patent Issued to Dyadic International
The Patent is entitled “Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose”.
Tuesday, March 25, 2014
Dyadic Issued New U.S. Patent
Dyadic International has been issued U.S. Patent No. 8,551,751 B2 entitled, "BX11 Enzymes Having Xylosidase Activity" by the United States Patent and Trademark Office.
Monday, November 11, 2013
Dyadic Welcomes New Chief Operating Officer
Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer.
Friday, May 10, 2013
Sixth U.S. Patent Issued to Dyadic International
U.S. Patent No. 7,794,962 - “High Throughput Screening of Expressed DNA Libraries in Filamentous Fungi”.
Thursday, October 14, 2010
Dyadic Granted Patent for High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi
Expands patent protection for Dyadic's C1 host technology platform for applications in cellulosic ethanol and other key markets.
Friday, October 20, 2006
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Microbial Analysis of MilkTrucks
A microbial study of milk trucks aims to improve dairy food safety and quality.
New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Unravelling the Metastatic Mechanism of Melanoma
Research has uncovered the mechanism of melanoma spreading; the findings could lead to a cure for the disease.
Diagnosing Bacterial Infections in Blood Samples
Researchers have diagnosed a bacterial infection from a blood sample in infants.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Creating Embryos with 'Heteroplasmy'
New discovery in genetic research could lead to treatments for mitochondrial diseases.
Molecular Alarm Clock Wakes Resting Ovules
Study of fruit flies yields discovery of a molecular "alarm clock" that activates resting ovules.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!